Business
Additional disclosure concerning Michael Owen
Additional disclosure concerning Michael Owen.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0933H Sareum Holdings PLC 29 July 2019 \n\n\n\n\n(AIM: SAR)\n\n\n29 July 2019\n\n\n\n \nSareum Holdings plc\n(\"Sareum\" or \"the Company\")\nAdditional disclosure concerning Michael Owen\n \nSareum Holdings PLC, the specialist small molecule drug development business, announced on 13 November 2018 the appointment of Michael Owen as a Non-Executive Director of the Company.\nIt has come to Sareum's attention that whilst his former directorship of BliNK Biomedical SAS (\"BliNK\") was detailed in that announcement, his former directorship of BliNK's subsidiary Blink Therapeutics Limited during the five years prior to that announcement should also have been included.\n \nFor further information, please contact: \n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser)\n\n\n\n\nChris Fielding / James Sinclair-Ford\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Nominated Broker)\n\n\n \n\n\n\n\nClaire Noyce\n\n\n020 3764 2341\n\n\n\n\nCitigate Dewe Rogerson (Media enquiries)\n\n\n \n\n\n\n\nShabnam Bashir/ Mark Swallow/ David Dible\n\n\n020 7638 9571\n\n\n\n \n- Ends -\n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END RDNEKLFLKDFLBBQ\n ","length":3733,"tagName":"div"}]